ADSTILADRIN
Total Payments
$1.6M
Transactions
7,169
Doctors
3,298
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.2M | 6,962 | 3,249 |
| 2023 | $382,069 | 207 | 109 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $672,478 | 99 | 41.5% |
| Unspecified | $446,072 | 78 | 27.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $264,116 | 70 | 16.3% |
| Food and Beverage | $183,287 | 6,701 | 11.3% |
| Travel and Lodging | $54,297 | 159 | 3.3% |
| Education | $817.78 | 62 | 0.1% |
Payments by Type
General
$1.2M
7,091 transactions
Research
$446,072
78 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | Ferring Pharmaceuticals AS | $314,551 | 0 |
| A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Ferring Pharmaceuticals AS | $65,655 | 0 |
| A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose | Ferring Pharmaceuticals AS | $48,866 | 0 |
| A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) | Ferring Pharmaceuticals AS | $17,000 | 0 |
Top Doctors Receiving Payments for ADSTILADRIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Urology | Bridgewater, NJ | $450,450 | 20 |
| Unknown | — | Virginia Beach, VA | $447,947 | 86 |
| Piyush Agarwal | Urology | Chicago, IL | $61,363 | 42 |
| , MD | Urology | Nashville, TN | $47,868 | 45 |
| , M.D | Urology | Virginia Beach, VA | $45,504 | 32 |
| , MD | Urology | Indianapolis, IN | $39,293 | 31 |
| , M.D | Urology | Denver, CO | $35,947 | 28 |
| , MD | Urology | Houston, TX | $34,840 | 31 |
| , MD | Urology | Decatur, GA | $23,741 | 20 |
| , MD | Urology | San Diego, CA | $20,827 | 14 |
| , M.D | Urology | Germantown, TN | $20,275 | 19 |
| , DR | Urology | Myrtle Beach, SC | $15,169 | 12 |
| , MD, PHD | Urology | Chicago, IL | $13,888 | 3 |
| , M.D | Urology | Los Angeles, CA | $13,392 | 12 |
| , MD PHD | Urology | Philadelphia, PA | $10,850 | 2 |
| , M.D | Urology | Rochester, MN | $8,887 | 5 |
| , M.D | Urology | Jeffersonville, IN | $7,774 | 8 |
| , MD | Urology | Houston, TX | $7,684 | 6 |
| , MD | Urology | Dallas, TX | $7,467 | 8 |
| , MD | Urology | Hanover, MD | $7,414 | 13 |
| , NURSE PRACTITIONER | Family | Cumming, GA | $7,148 | 21 |
| , MD | Urology | Stanford, CA | $7,058 | 8 |
| , M.D | Urology | Houston, TX | $4,675 | 4 |
| , MD | Urology | Minneapolis, MN | $4,480 | 3 |
| , MD, MPHIL | Urology | Charleston, SC | $4,383 | 4 |
Ad
Manufacturing Companies
- Ferring Pharmaceuticals Inc. $1.1M
- Ferring Pharmaceuticals AS $517,624
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 3,298
- Transactions 7,169
About ADSTILADRIN
ADSTILADRIN is a drug associated with $1.6M in payments to 3,298 healthcare providers, recorded across 7,169 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals Inc..
Payment data is available from 2023 to 2024. In 2024, $1.2M was paid across 6,962 transactions to 3,249 doctors.
The most common payment nature for ADSTILADRIN is "Consulting Fee" ($672,478, 41.5% of total).
ADSTILADRIN is associated with 4 research studies, including "ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States" ($314,551).